Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
157 Results for "
B-Raf inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (157)
157 Results for "B-Raf inhibitor" in MCE Product Catalog:
Cat. No.: HY-184875
CAS No.: 342434-07-5
Target:
Research Areas:
B-Raf-IN-21 is a B-Raf kinase inhibitor with a Kd of 4.8 nM and an IC50 of 6 nM. B-Raf-IN-21 can be used for the research of stroke .
Cat. No.: HY-177946
CAS No.: 1445582-05-7
RAF-IN-4 (Compound 120) is a Raf Kinase inhibitor. RAF-IN-4 shows IC50 values of 134.3, 118.6 and 276.7 nM for B-Raf, B-Raf (V600E) and C-Raf. RAF-IN-4 can inhibit the proliferation of cancer cells by blocking the Raf signaling pathway. RAF-IN-4 can be used for research of cancer, such as lung cancer and breast cancer .
Cat. No.: HY-10966G
CAS No.: 405554-55-4
Cat. No.: HY-109080R
CAS No.: 1446113-23-0
Synonyms: HM95573 (Standard); GDC-5573 (Standard); RG6185 (Standard)
Target:
Research Areas:
Belvarafenib (Standard) is the analytical standard of Belvarafenib (HY-109080). This product is intended for research and analytical applications. Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively .
Cat. No.: HY-11004R
CAS No.: 878739-06-1
Target:
Research Areas:
AZ 628 (Standard) is the analytical standard of AZ 628 (HY-11004). This product is intended for research and analytical applications. AZ 628 is a pan-Raf Kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
Cat. No.: HY-11043
CAS No.: 950525-20-9
PF-0419789 is a BRAF (V600E) inhibitor that can be used to study BRAF V600 mutant solid tumors .
Cat. No.: HY-13810
CAS No.: 1111636-35-1
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .
Cat. No.: HY-180329
CAS No.: 2417296-83-2
CG 858-Neg (compound 13) is a negative control for Thalidomide (HY-14658)-derived PROTAC degraders, targeting BRAF and BRAF V600E with Ki values of 9.5 nM and 14.4 nM, respectively. CG 858-Neg inhibits downstream ERK phosphorylation and suppresses BRAF V600E-driven melanoma (e.g., A375 cells, IC50=492 nM) and colorectal cancer (e.g., HT-29 cells, IC50=459 nM) cells. CG 858-Neg can be used in research related to melanoma and colorectal cancer .
Cat. No.: HY-123799
CAS No.: 502638-39-3
Target:
Research Areas:
B-699393 (Compound 17) is a BRAF inhibitor (Kd = 7.2 nM) that can cross the blood-brain barrier. SB-699393 can be used for research on stroke .
Cat. No.: HY-164400
CAS No.: 839707-55-0
SIJ1777 is a GNF-7 (HY-10943) derivative, possesses potent anti-cancer effects on melanoma cells harboring BRAF class I/II/III mutations. SIJ1777 substantially inhibits the activation of MEK, ERK, and AKT. SIJ1777 remarkably induces apoptosis and significantly blocks migration, invasion, and anchorage-independent growth of melanoma cells harboring BRAF class I/II/II mutations .
Synonyms: LUT014
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Omzirafenib (LUT014) is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. Omzirafenib inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. Omzirafenib is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. Omzirafenib can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .
Cat. No.: HY-108887
CAS No.: 1884226-20-3
Anticancer agent 124 is an orally active, highly selective and potent pan RAF inhibitor. Anticancer agent 124 inhibits MAPK signalling in BRAF V600E, NRAS and KRAS mutant tumor cells .
Cat. No.: HY-N3634
CAS No.: 775351-91-2
Target:
Cat. No.: HY-175831
CAS No.: 3027070-47-6
BRAFV600E-IN-2 is a BRAF V600E inhibitor with IC50 ≤10 nM. BRAFV600E-IN-2 has anti-tumor activity .
Cat. No.: HY-107779R
CAS No.: 1392429-79-6
Target:
Research Areas:
BI-882370 (Standard) is the analytical standard of BI-882370 (HY-107779). This product is intended for research and analytical applications. BI-882370 is a potent and selective RAF Kinase inhibitor that binds to the ATP binding site of the Kinase positioned in the DFG-out (inactive) conformation of the BRAF Kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF Kinases with IC50s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family Kinases .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
